Regentis Biomaterials

Company Overview

Snapshot

Founded in September 2004 by Prof. Dror Seliktar, Regentis Biomaterials operates with 1–10 employees. The company has raised a total of $43.5M across four funding rounds from eight investors. Regentis Biomaterials became public on NASDAQ in September 2025.

Business overview

Regentis Biomaterials is a tissue-repair company focused on developing and commercializing a hydrogel platform for regenerating damaged tissue, particularly in orthopedics. Its core product, GelrinC, is a cell-free, off-the-shelf hydrogel implant designed for treating painful articular knee cartilage injuries. The implant acts as a scaffold, gradually resorbing as new cartilage forms, and meets international safety and quality standards including GMP and ISO 13485. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Pharma & Medical Biotechnology, serving healthcare providers in markets such as Germany, the Netherlands, Belgium, Poland, Denmark, and the United States.

Strategic signal

In June 2026, Regentis Biomaterials announced plans to commence European surgeon training for GelrinC, accelerating commercial launch preparations for its knee cartilage repair product. This move signals a significant step towards market penetration and commercialization in Europe, indicating a strategic focus on expanding product availability and adoption in key international markets.

Company Intelligence Q&A

What is the primary focus of Regentis Biomaterials' product development?

Regentis Biomaterials primarily focuses on developing and commercializing a hydrogel platform for the repair of damaged tissue, with current efforts concentrated on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue.

What is GelrinC and how does it function?

GelrinC is Regentis Biomaterials' first commercial product, a cell-free, off-the-shelf hydrogel implant for treating painful injuries to articular knee cartilage. It is injected as a liquid, conforms to the lesion, and becomes a semisolid implant after UV light exposure, acting as a scaffold that gradually erodes as new cartilage replaces it.

When did Regentis Biomaterials become a publicly listed company?

Regentis Biomaterials became publicly listed on NASDAQ in September 2025.

What significant manufacturing advancement did Regentis Biomaterials announce in March 2026?

In March 2026, Regentis Biomaterials developed and patented a new solvent-free manufacturing process that increases GelrinC production yield by 400%.

What recent strategic move did Regentis Biomaterials make regarding its European commercial launch?

In June 2026, Regentis Biomaterials announced it would commence European surgeon training for GelrinC in knee cartilage repair, accelerating its commercial launch preparations in the region.